Why Is the Meningococcal Vaccine Required for PNH?
At a Glance
Medicines called complement inhibitors used to treat PNH weaken part of the immune defense and greatly increase the risk of meningococcal disease. MenACWY and MenB vaccines, possible preventive antibiotics, a Patient Safety Card, and urgent care for symptoms are key safety measures.
In this answer
4 sections
If you are taking a complement inhibitor for Paroxysmal Nocturnal Hemoglobinuria (PNH), you are required to get meningococcal vaccines and carry a Patient Safety Card because these medications increase your risk of a rare, serious bacterial infection. To manage PNH, these drugs block specific parts of your immune system. While this stops the destruction of your red blood cells, it also weakens your body’s defense against “encapsulated bacteria”—bacteria protected by a tough outer coating—most notably Neisseria meningitidis [1][2]. Because the risk persists even after vaccination, strict safety protocols, including emergency action plans and safety cards, are required [3][4].
How Different PNH Treatments Affect Your Immune System
Complement inhibitors are very effective at managing PNH, but they work by interrupting the complement system, a crucial part of your immune defenses. The exact effect depends on which medication you take:
- C5 Inhibitors (eculizumab/Soliris and ravulizumab/Ultomiris): These drugs block the “terminal complement pathway.” Normally, this pathway creates a specialized tool called the membrane attack complex, a set of immune proteins that punches holes in and destroys invading encapsulated bacteria [1][2]. Blocking this pathway increases the risk of developing meningococcal disease by more than 1,000 times compared to the general population [2][5].
- C3 Inhibitors (pegcetacoplan/Empaveli): This medication blocks the complement system earlier in the process (the proximal pathway). Because it works differently, it not only increases the risk of meningococcal infections but also requires protection against other encapsulated bacteria, such as pneumococcus (Streptococcus pneumoniae) and Haemophilus influenzae type b (Hib) [6].
Why Vaccines (and Sometimes Antibiotics) Are Required
To help lower these risks, medical guidelines state that you must be vaccinated before starting treatment [3][4].
- For all complement inhibitors, you need vaccines against both MenACWY (which covers serogroups A, C, W, and Y) and MenB (which covers serogroup B) [3].
- If you take pegcetacoplan, you will also need vaccines against pneumococcus and Hib [6].
Timing and Urgent Treatment: Ideally, these vaccines should be given at least two weeks before you start your PNH medication so your body has time to build immunity [6]. However, if you are severely ill and need PNH treatment immediately, your doctor will not delay your care. Instead, they will start your treatment, give you the vaccines as soon as possible, and prescribe short-term preventive antibiotics (a “bridge”) to protect you until the vaccines take effect [6][5].
Vaccines Are Not a Perfect Shield: Vaccines stimulate your immune system to create antibodies, but they do not cover every single strain of bacteria, nor do they fully restore your immune system’s ability to kill the bacteria while on these drugs [4][7]. Breakthrough infections can happen even in fully vaccinated patients [7][8]. Because of this ongoing risk, many doctors recommend taking daily preventive antibiotics (prophylaxis) for the entire duration of your complement inhibitor therapy [5].
The Vital Role of Your Patient Safety Card
Because breakthrough infections are possible, early recognition and rapid treatment can be life-saving [5][9].
Your Patient Safety Card is an essential medical tool. Emergency room staff may not be familiar with the specific immune-blocking effects of PNH medications. Your card immediately alerts them that:
- You are on a medication that significantly increases your risk of meningococcal disease [8][10].
- Any signs of infection must be evaluated urgently, regardless of whether you have been vaccinated or are taking preventive antibiotics [5].
- If meningococcal disease is suspected, you may need immediate intravenous (IV) antibiotics, which is a clinical treatment target for suspected serious bacterial infections [9][5].
You must carry this card with you at all times. Additionally, because these medications stay in your system long after your last infusion or injection, you must continue carrying the card for a specific period after you stop treatment. Follow the exact timeline listed on your card or provided by your doctor [8][10].
Emergency Symptoms to Watch For
Meningococcal disease can progress from mild symptoms to a severe condition in a matter of hours [9]. If you develop signs of an infection, seek emergency medical care immediately. Do not wait for a routine clinic appointment, and do not assume that a lack of a rash means you are safe [5][11].
Go to the nearest emergency room or call emergency services if you experience sudden, severe illness, or any of the following:
- Fever (Often an early sign, but not always present) [12][13]
- Severe or unusual headache [12]
- Stiff neck (Difficulty touching your chin to your chest) [12]
- A rash or tiny purple/red spots on the skin (petechiae) [12]
- Nausea, vomiting, or severe diarrhea [13][14]
- Confusion, reduced alertness, or extreme muscle pain [13]
A note for family and caregivers: Early invasive meningococcal disease can sometimes look like a standard viral illness [14][9]. If the patient becomes confused, collapses, or is too ill to speak, call emergency services immediately. Tell the dispatcher and the medical staff the exact name of their PNH medication and that they are at a highly increased risk for meningococcal disease. Ensure triage staff sees the Patient Safety Card immediately upon arrival.
Common questions in this guide
Why do PNH complement inhibitors increase the risk of meningococcal infection?
Which vaccines are needed before starting a complement inhibitor for PNH?
What if I need to start PNH treatment before my vaccines take effect?
Can I still get meningococcal disease after vaccination?
Why do I need to carry a Patient Safety Card during PNH treatment?
What symptoms require emergency help while I am taking a PNH complement inhibitor?
Should I take preventive antibiotics while receiving a PNH complement inhibitor?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on Paroxysmal nocturnal hemoglobinuria.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Have I received all the required doses and boosters for the MenACWY and MenB vaccines, and are any other vaccines (like pneumococcal or Hib) required for my specific PNH medication?
- 2.Should I be taking daily preventive antibiotics (prophylaxis) while on this treatment, and if so, for how long?
- 3.If I need to start my PNH medication urgently, before my vaccines take full effect, what is our short-term antibiotic plan?
- 4.How long after my last dose of this medication do I need to continue carrying my Patient Safety Card?
- 5.If I develop sudden severe symptoms when the clinic is closed, exactly where should I go, and who should I call?
References
References (14)
- 1
Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders.
Vieira GD, Boldrini VO, Mader S, et al.
Multiple sclerosis and related disorders 2025; (95()):106311 doi:10.1016/j.msard.2025.106311.
PMID: 39983521 - 2
Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals.
Ispasanie E, Muri L, Schubart A, et al.
Frontiers in immunology 2021; (12()):747594 doi:10.3389/fimmu.2021.747594.
PMID: 34691058 - 3
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.
Mbaeyi SA, Bozio CH, Duffy J, et al.
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 2020; (69(9)):1-41 doi:10.15585/mmwr.rr6909a1.
PMID: 33417592 - 4
Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients.
Langereis JD, van den Broek B, Franssen S, et al.
Blood advances 2020; (4(15)):3615-3620 doi:10.1182/bloodadvances.2020002497.
PMID: 32766853 - 5
High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.
McNamara LA, Topaz N, Wang X, et al.
MMWR. Morbidity and mortality weekly report 2017; (66(27)):734-737 doi:10.15585/mmwr.mm6627e1.
PMID: 28704351 - 6
Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings.
Kelly RJ, Nishimori H, Horneff R, et al.
Research and practice in thrombosis and haemostasis 2024; (8(4)):102416 doi:10.1016/j.rpth.2024.102416.
PMID: 38812989 - 7
Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.
Konar M, Granoff DM
Blood 2017; (130(7)):891-899 doi:10.1182/blood-2017-05-781450.
PMID: 28630122 - 8
Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature.
Galli N, Pettine L, Panigada M, et al.
Frontiers in immunology 2023; (14()):1269325 doi:10.3389/fimmu.2023.1269325.
PMID: 37854608 - 9
High risk and low incidence diseases: Meningococcal disease.
Cejin MC, Koyfman A, Long B
The American journal of emergency medicine 2026; (99()):114-122 doi:10.1016/j.ajem.2025.09.031.
PMID: 41016083 - 10
A Case of Fulminant Meningococcemia: It Is All in the Complement.
Hawkins KL, Hoffman M, Okuyama S, Rowan SE
Case reports in infectious diseases 2017; (2017()):6093695 doi:10.1155/2017/6093695.
PMID: 28808592 - 11
Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy.
Kavaz Tufan A, Ozak Batibay F, Kaya Aksoy G, et al.
Children (Basel, Switzerland) 2024; (11(10)) doi:10.3390/children11101164.
PMID: 39457129 - 12
Nonspecific symptoms dominate at first contact to emergency healthcare services among cases with invasive meningococcal disease.
Hovmand N, Christensen HC, Lundbo LF, et al.
BMC family practice 2021; (22(1)):240 doi:10.1186/s12875-021-01585-8.
PMID: 34847878 - 13
Range of Clinical Manifestations Caused by Invasive Meningococcal Disease Due to Serogroup W: A Systematic Review.
Bertrand-Gerentes I, Fanchon L, Coste F, et al.
Infectious diseases and therapy 2023; (12(10)):2337-2351 doi:10.1007/s40121-023-00869-z.
PMID: 37751017 - 14
[Meningococcemia without meningitis: A report of two cases].
Poizeau F, Cormerais M, Darrieux L, et al.
La Revue de medecine interne 2016; (37(3)):206-8.
PMID: 26338027
This page is for informational purposes only and does not constitute medical advice. Ask your hematology team about your vaccines, antibiotics, Patient Safety Card, and emergency plan.